Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adina Voiculescu

Nephrology Boston, MA Medical Doctor

NPI 1366761348 CMS profile 715618

75 Francis St, Bwh Renal Division Mrb4, Boston, MA 02115

Open in the dashboard

General payments

$15,619

22 records reported · program years 2019–2025

Research payments

$350

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adina Voiculescu of Boston, MA is reported in the CMS Open Payments database as having received $15,619 across 22 general payments and $350 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $454 3
2024 Research $350 1
2023 General $3,410 9
2022 General $305 4
2021 General $5,175 2
2020 General $6,125 3
2019 General $150 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adina Voiculescu
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Adina Voiculescu were reported at $454. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Adina Voiculescu Nephrology median Middle half National median
2019 $150 $236 $90–$588 $163
2020 $6,125 $135 $46–$364 $114
2021 $5,175 $202 $67–$551 $132
2022 $305 $242 $77–$695 $149
2023 $3,410 $254 $84–$766 $160
2024 $0 $300 $99–$852 $164
2025 $454 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Surmodics, Inc. $9,100 4 payments
  2. Horizon Therapeutics plc $5,413 9 payments
  3. Sonavex, Inc. $285 1 payment
  4. Alexion Pharmaceuticals, Inc. $150 1 payment
  5. Laminate Medical Technologies inc. $132 1 payment
  6. Bard Peripheral Vascular, Inc. $128 1 payment
  7. Relypsa, Inc. $121 1 payment
  8. Bayer HealthCare Pharmaceuticals Inc. $117 1 payment
  9. Medtronic, Inc. $113 1 payment
  10. CorMedix Inc. $41 1 payment
  11. Other $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $9,100 4 payments
  2. Honoraria $5,210 3 payments
  3. Food and Beverage $1,154 11 payments
  4. Education $124 3 payments
  5. Travel and Lodging $31 1 payment
Products named General payments · program years 2019–2025
  1. AVess FIH $9,100 4 payments
  2. KRYSTEXXA $5,413 9 payments
  3. EchoSure $285 1 payment
  4. EchoMark $285 1 payment
  5. Soliris $150 1 payment
  6. VasQ External Support $132 1 payment
  7. COVERA $128 1 payment
  8. Korsuva $121 1 payment
  9. Kerendia $117 1 payment
  10. Argyle $113 1 payment
  11. Other $61 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Surmodics, Inc. $350 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

331

Median for Nephrology: 954

Drug cost

$123,703

Median for Nephrology: $127,050

Branded share of claims

18.7%

Median for Nephrology: 17.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Velphoro Sucroferric Oxyhydroxide Brand 17 $92,932
Eliquis Apixaban Brand 31 $25,926
Labetalol Hcl Generic 13 $1,282
Calcitriol Generic 33 $1,004
Torsemide Generic 49 $710
Losartan Potassium Generic 39 $392
Clopidogrel Clopidogrel Bisulfate Brand 14 $368
Amlodipine Besylate Generic 40 $277
Lisinopril Generic 29 $211
Furosemide Generic 11 $189

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,003 Part D prescribers listed as Nephrology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$141,459

Medicare's payments for the services billed

Medicare patients

477

Average age 71

Services billed

1,760

223 women, 254 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 59%
Ischemic heart disease 57%
Heart failure 54%
Arthritis 49%
Depression 40%
Atrial fibrillation 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

23 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record